Related Experiment Videos
Pharmacogenomics of childhood acute lymphoblastic leukemia
T L Brenner1, C H Pui, W E Evan
1Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN 38105, USA.
Abstract:
Approximately 80% of children with acute lymphoblastic leukemia (ALL) can be cured with modern therapy. Despite this success, the number of cases of relapsed ALL remains greater than the number of new cases of most childhood cancers. New strategies are needed to develop curative therapy for the 20% of patients who are not being cured today, and to develop less toxic and less onerous treatment for ALL patients. Molecular genetics has already provided important insights to the mechanisms of leukemogenesis and is now routinely used to define the prognosis and guide treatment intensity for childhood ALL. Pharmacogenomics is a burgeoning field that aims to elucidate inherited differences in drug disposition and treatment response, toward individualizing therapy to enhance efficacy and reduce toxicity. Herein, we review recent progress in thesefields as they relate to childhood ALL, and discuss the promise they hold to further enhance treatment of the most common cancer in children.
Insights
Modern therapy cures 80% of childhood acute lymphoblastic leukemia (ALL), but relapsed cases persist. Advances in molecular genetics and pharmacogenomics offer new strategies for treating resistant ALL and improving patient outcomes.
Area of Science:
- Pediatric Oncology
- Molecular Genetics
- Pharmacogenomics
Background:
- Acute lymphoblastic leukemia (ALL) is the most common childhood cancer.
- Current therapies achieve high cure rates (approx. 80%), but a significant proportion of patients experience relapse.
- Relapsed ALL presents a challenge, necessitating novel therapeutic strategies and less toxic treatments.
Purpose of the Study:
- To review recent advancements in molecular genetics and pharmacogenomics relevant to childhood ALL.
- To discuss the potential of these fields in developing personalized and more effective treatments.
- To explore strategies for improving cure rates and reducing treatment burden in ALL.
Main Methods:
- Review of current literature on molecular genetics in leukemogenesis.
- Analysis of pharmacogenomic studies related to drug response in ALL.
- Discussion of the integration of genetic insights into clinical practice.
Main Results:
- Molecular genetics provides crucial insights into ALL development and prognosis.
- Pharmacogenomics holds promise for tailoring ALL therapy to individual patients.
- These fields are key to enhancing efficacy and minimizing toxicity in ALL treatment.
Conclusions:
- Continued research in molecular genetics and pharmacogenomics is essential for advancing childhood ALL therapy.
- Personalized treatment approaches based on genetic profiles can improve outcomes for ALL patients.
- Future strategies will focus on overcoming treatment resistance and reducing long-term side effects.